Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 11/20 | 0.54 |
| ▸ | MMP9 | P14780 | 11/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | CRY1 | Q16526 | 5/20 | 0.46 |
| ▸ | CRY2 | Q49AN0 | 5/20 | 0.46 |
| ▸ | PER2 | O15055 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5131313 | 1.00 | MMP2 (0.54) | MMP2MMP9MCL1CRY1CRY2 | |
| SCHEMBL5131397 | 0.85 | MMP2 (0.74) | MMP2MMP9MEN1KMT2ALMNA | |
| SCHEMBL5131359 | 0.85 | MMP2 (0.74) | MMP2MMP9MEN1KMT2ALMNA | |
| SCHEMBL8019407 | 0.84 | MMP2 (0.76) | MMP2MMP9 | |
| SCHEMBL8026858 | 0.84 | MMP2 (0.76) | MMP2MMP9 | |
| SCHEMBL14222645 | 0.84 | MMP2 (0.61) | MMP2MMP9MCL1CRY1CRY2 | |
| SCHEMBL8391053 | 0.84 | MMP2 (0.76) | MMP2MMP9 | |
| SCHEMBL5127877 | 0.77 | MMP2 (0.74) | MMP2MMP9 | |
| SCHEMBL14223317 | 0.77 | MMP2 (0.74) | MMP2MMP9CRY1CRY2PER2 | |
| SCHEMBL5125315 | 0.77 | MMP2 (0.74) | MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080085893-A1 | MATRIX METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085893-A1 | MATRIX METALLOPROTEASE INHIBITORS | MMP3, MMP7, MMP9 | MMP2 5/4885MMP9 3/4885MCL1 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.